Data showing the circumvention of oxaliplatin resistance by vatalanib in colon cancer
We have recently reported that vatalanib, an orally active small molecule multi-tyrosine kinase inhibitor (Hess-Stumpp et al., 2005 [1]), can sensitize multidrug resistant (MDR) colon cancer cells to chemotherapy under hypoxia by inhibiting two MDR transporters ABCB1 and ABCG2 (To et al., 2015 [2])....
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Elsevier
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789311/ |